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Abstract
Background: Vulnerabilities to dependence on addictive substances are substantially heritable complex disorders whose
underlying genetic architecture is likely to be polygenic, with modest contributions from variants in many individual genes.
‘‘Nontemplate’’ genome wide association (GWA) approaches can identity groups of chromosomal regions and genes that,
taken together, are much more likely to contain allelic variants that alter vulnerability to substance dependence than
expected by chance.
Methodology/Principal Findings: We report pooled ‘‘nontemplate’’ genome-wide association studies of two independent
samples of substance dependent vs control research volunteers (n=1620), one European-American and the other African-
American using 1 million SNP (single nucleotide polymorphism) Affymetrix genotyping arrays. We assess convergence
between results from these two samples using two related methods that seek clustering of nominally-positive results and
assess significance levels with Monte Carlo and permutation approaches. Both ‘‘converge then cluster’’ and ‘‘cluster then
converge’’ analyses document convergence between the results obtained from these two independent datasets in ways
that are virtually never found by chance. The genes identified in this fashion are also identified by individually-genotyped
dbGAP data that compare allele frequencies in cocaine dependent vs control individuals.
Conclusions/Significance: These overlapping results identify small chromosomal regions that are also identified by genome
wide data from studies of other relevant samples to extents much greater than chance. These chromosomal regions contain
more genes related to ‘‘cell adhesion’’ processes than expected by chance. They also contain a number of genes that
encode potential targets for anti-addiction pharmacotherapeutics. ‘‘Nontemplate’’ GWA approaches that seek chromosomal
regions in which nominally-positive associations are found in multiple independent samples are likely to complement
classical, ‘‘template’’ GWA approaches in which ‘‘genome wide’’ levels of significance are sought for SNP data from single
case vs control comparisons.
Citation: Drgon T, Zhang P-W, Johnson C, Walther D, Hess J, et al. (2010) Genome Wide Association for Addiction: Replicated Results and Comparisons of Two
Analytic Approaches. PLoS ONE 5(1): e8832. doi:10.1371/journal.pone.0008832
Editor: Katharina Domschke, University of Muenster, Germany
Received July 13, 2009; Accepted December 21, 2009; Published January 21, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This study was fully supported by the National Institutes of Health (NIH) Intramural Research Program (National Institute on Drug Abuse). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This research was supported financially by the NIH
Intramural Research Program, National Institute on Drug Abuse, Department of Health and Human Services. Support for dbGAP data came from the NIH Genes,
Environment and Health Initiative (GEI) (U01 HG004422)/Gene Environment Association Studies (GENEVA) which received assistance with phenotype
harmonization, genotype cleaning, and study coordination from the GENEVA Coordinating Center (U01 HG004446), assistance with data cleaning from the
National Center for Biotechnology Information, and assistance with collection of datasets and samples by the Collaborative Study on the Genetics of Alcoholism
(COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392) and the Family Study of Cocaine Dependence (FSCD;
R01 DA013423). Support for genotyping dbGAP samples at the Johns Hopkins University Center for Inherited Disease Research came through (U01HG004438), the
National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse and the NIH contract ‘‘High throughput genotyping for studying the
genetic contributions to human disease’’ (HHSN268200782096C). dbGaP datasets were obtained at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000092.v1.p1 through dbGaP accession number phs000092.v1.p.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: guhl@intra.nida.nih.gov
Introduction
Vulnerability to addictions is a complex trait with substantial
genetic influences that are documented by data from family,
adoption and twin studies [1–4]. Twin studies also document
shared heritable influences on vulnerability to dependence on
addictive substances from different pharmacological classes (eg
nicotine and stimulants) [2,3,5]. In individuals from most
populations, each gene’s variants are likely to contribute modestly
to substance dependence vulnerability. Contributions of nicotinic
receptor gene variants to individual differences in smoking
quantity [6–10] and acetaldehyde dehydrogenase/alcohol dehy-
drogenase variants to risk for alcohol dependence in Asians may
provide larger effects of variants at single loci [11,12]. However,
combined data from linkage and initial genome wide association
studies (GWA) [6,13–17] suggest that most genetic effects on
vulnerability to substance dependence are likely to be polygenic.
GWA is a method of choice for identifying genes whose variants
influence vulnerability to complex disorders. GWA approaches
that we term ‘‘template’’ seek to identify ‘‘genome wide’’ levels of
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28) for case vs control differences in single
samples of individually genotyped individuals. ‘‘Replication’’ of
GWA results in these ‘‘template’’ GWA analyses is based on
identification of genome wide significance for the same SNP with
the same phase of association in each of multiple independent
samples.
However, with underlying polygenic genetic architectures,
effects of only modest magnitude are likely to be identified in
many single samples of practical size. We and others have
developed ‘‘nontemplate’’ GWA analyses to address highly
heritable complex phenotypes for which there is little evidence
for many genes of major effect. These analyses have focused on
identification of nominally significant case vs control allele
frequency differences at several nearby SNP markers in multiple
independent samples. Identifying ‘‘clustered’’ positive findings at
several nearby SNPs and finding clustered positive results in several
independent samples provide some of the best available controls
for technical errors and for the large numbers of repeated
comparisons that are fundamental to GWA. There is no consensus
concerning criteria for declaring ‘‘replication’’ of GWA results in
the absence of genome wide significance for the same SNP with
the same phase of association in multiple independent samples
[18–23]. Several considerations have prompted differing approach-
es to 1) combining and comparing GWA datasets and 2) declaring
that association between sets of nearby SNPs and a complex
disorder is ‘‘replicated’’ in the absence of genome wide significance
for any result. Underlying functional haplotypes contributing to
disease vulnerability may be tagged differently by different SNP
sets in different samples. Allelic heterogeneity can result in 1)
contributions of different variants within the same gene and 2)
differences in the predominant variants in a gene that influence the
phenotype in different samples. Meta-analyses often combine data
from studies that have examined alleles of different sets of SNPs.
We now report ‘‘nontemplate’’ GWA [24] studies that compare
allele frequencies for almost 870,000 autosomal SNPs in each of
two independent samples (one European-American and the second
African-American) of controls vs polysubstance abusers who report
heavy use and dependence on at least one illegal substance. We
have characterized and collected these case and control samples at
a single site. We use a nontemplate GWA approach with DNA
pooling to study the genetics of this illegal behavior. We analyze
genes that are identified by ‘‘replicated’’ results from these data in
each of two ways that appear to complement each other (though
they are not independent of each other): 1) ‘‘converge then cluster’’,
based on identification of SNPs within a gene that a) display
nominally significant case vs control allele frequency differences in
each of these two samples and b) lie near other SNPs with the same
properties, and 2) ‘‘cluster then converge’’, based on SNPs within
genes that are identified in each of the two samples by clusters of
SNPs that a) display nominally significant case vs control allele
frequency differences and b) lie near other SNPs with the same
properties. Since approach (2) does not require that the identical
SNPs display nominally significant results in each of several
samples, it is especially useful for evaluating concordance between
GWA datasets that use different sets of SNPs. We can thus apply
this approach to examining the concordance between addiction
and co-occurring traits likely to display complex genetic influences
[25] using empirical Monte Carlo statistics to assess the significance
of results. We discuss this work in light of its technical and analytic
limitations and in its similarities and differences with ‘‘template’’
GWA analyses that seek associations that display genome-wide
significance, typically in phenotypes that display oligogenic genetic
architectures and/or in larger samples that are often recruited in
multiple locations. We also describe the ways in which these pooled
genotype data identify a number of the same genomic regions that
are identified by recently available dbGAP datasets that provide
individual genotyping for cocaine-dependent and nondependent
comparison groups.
Results
Variation and Power Calculations
The pooling approach used herein provides evidence for good
assessment of allele frequency differences and variation in these
estimates. SNP allele frequency assessments made herein display
modest variability and good fits between individual and pooled
genotyping with mean correlation of 0.98+/20.002 (standard
error, SEM, Fig. 1). Validating studies with similar arrays add to
confidence in this data [13,14,26–34]. SEM for the variation
among three replicate studies of each DNA pool was +/20.03.
SEM for the variation between the ca. 20 pools studied for each
ethnicity/phenotype group was +/20.02. These estimates of
variability allowed us to estimate 0.8 and 0.9 power to detect 5 and
10% allele frequency differences in the African American sample
sizes described here. We had 0.76 and 0.99 power to detect 5 and
10% allele frequency differences in European American samples.
Corresponding false negative probabilities for approach 1 (converge
then cluster) are thus 0.39 and 0.11, since this approach requires
nominally positive results for the same SNP from both samples.
Statistical power for the analysis of these samples can also be
calculated using ‘‘gene detective’’ [25]; this power rises from 0.1 to
Figure 1. Validation graph of the relationships between
observed (y axis) and expected (x axis) allele frequency data
for Affymetrix 6.0 arrays. ‘‘Expected’’ frequencies come from
individual genotyping of individuals. These individuals were assigned
to three sets of pools each containing 2, 5 and 15 CEPH individuals
(total of 81 individuals). Arctan A/B represent the ‘‘observed’’ measures
of allele frequency and are arctangents of the A/B hybridization ratios
for this set of pools of individuals. In this figure we have only used SNPs
that show at least 10% difference in the expected values across the set
of pools (total of 146,000 SNPs). We have obtained similar data from
studies validating 500k,100k, 10k and HuSNP arrays [14–16]. Note that
DNA used for hybridization is less than that recommended for
individual genotyping (135 vs 225 ng) in order to avoid saturation of
hybridization signals for some array features. Error bars indicate SEM.
doi:10.1371/journal.pone.0008832.g001
GWA in Addiction
PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8832ca. 0.9 as risk to a sib of an affected individual (ls) rises from 1.2 to
2.5 [35].
‘‘Converge Then Cluster’’
In our assessment of allele frequency differences between
abusers and controls 83,202 and 75,327 SNPs displayed
‘‘nominally positive’’ t values with p,0.05 in African- and
European-American samples, respectively. There was substantial
convergence of the results from these two GWA datasets using the
non-template (1) ‘‘converge then cluster’’ GWA analysis approach.
11,037 of the 870,000 tested SNPs displayed ‘‘reproducible’’
results, as defined using this approach. These SNPs thus displayed
nominally significant abuser vs control allele frequency differences
in each of the two samples. This overall convergence was much
greater than anticipated based on chance. None of 100,000 Monte
Carlo simulation trials that each began by selecting 83,202 and
75,327 random SNPs displayed as many as 11,037 nominally
significant results in both samples (p,0.00001). None of 10,000
permutation trials displayed results from permuted datasets that
matched or exceeded the 11,037 SNPs actually observed
(p,0.0001 by permutation analyses). These 11,037 SNPs thus
provide the ‘‘reproducibly positive SNPs’’ for analytic approach (1).
The reproducibly-positive SNPs identified by abuser/control
comparisons in both European- and African-American samples
cluster together in small chromosomal regions (Fig. 2) to extents
much greater than anticipated by chance. 937 of the reproducibly-
positive SNPs from approach (1) lie in 271 clusters of $3 SNPs
that are separated from each other by #25kb. This degree of
clustering was never identified by chance (Monte Carlo
p,0.00001). These clusters of reproducibly positive SNPs from
analytic approach (1) identify 104 genes (Tables 1, 2). Randomly
selected SNPs never cluster by chance within genes to the extent
observed here (Monte Carlo p,0.00001).
We would anticipate the observed, highly significant clustering
of SNPs that display nominally positive results if many of these
reproducibly positive SNPs lay near and were in linkage
disequilibrium with functional allelic variants that distinguished
substance dependent subjects from control subjects, but not if they
Figure 2. Chromosomal distributions of abuser/control t values, clustered positive SNPs, and candidate positive genes (Table 1).
Blue boxes: t values of the abuser control differences from 870,000 SNPs studied here. Values from European-Americans: right side, from African-
Americans: left side. Red circles: Positions of the SNPs whose data yield clustered positive values. Yellow triangles: positions of clustered positive results
that support genes listed in Table 1. Scale bar (grey): 25 Mb.
doi:10.1371/journal.pone.0008832.g002
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here are likely to receive contributions from both the extent of
linkage disequilibrium among the clustered, nominally positive
SNPs and the extent of linkage disequilibrium between these SNPs
and the functional haplotype(s) that lead to the association with
substance dependence.
‘‘Cluster Then Converge’’
Non-template analytic approach (2) ‘‘cluster then converge’’
also assessed the significance of the 83,202 and 75,327 SNPs that
displayed nominally positive results in African-American and
European-American samples, respectively. 17,849 SNPs from
African American and 15,779 SNPs from European American
samples provide clusters, within each sample, of at least 4
nominally positive SNPs that lie within #10kb of each other.
2,142 of these SNPs lie within clusters that identify the same genes
in both African- and European-American samples (Tables 1, 2).
The 341 genes that are identified in this way (Table S1) are never
identified by chance, using this approach, in 100,000 Monte Carlo
II simulation trials (p,0.00001)([36] and Materials and Methods).
The genes identified using approach (2) overlap with K of the
genes identified using approach (1) (Table 2).
Controls for Alternative Hypotheses
Controls for occult stratification do not appear to provide
convincing alternative explanations for the data obtained here.
Only 22 of the 937 clustered, reproducibly positive SNPs that we
identify here using approach (1) also display sizable allele
frequency differences based on ethnicity. Since we would have
expected 24 by chance, it appears highly unlikely that stratification
based on racial/ethnic differences between each abuser and
corresponding control samples provides a major basis for the
addiction-associated allelic variants identified herein. Principal
components analyses identify robust principal components that
cleanly separate African-American from European-American
samples and account for about 94% of the variance when both
samples are analyzed together (data not shown). However, there is
significant distinction between substance dependent vs control
pools based on additional principal components that are
orthogonal to those that distinguish individuals with African vs
European heritages. Analyses of the likelihood that substance
dependent samples would be distinguished from control samples
by this principal component based on chance yield p=0.00003
and p=0.057 probabilities in European- and African-American
samples, respectively (data not shown).
Assay noise also fails to provide a convincing alternative
explanation for the data reported herein. When we examined the
overlap between the clustered positive SNPs and the 10% of the
SNPs for which the correlations between observed and expected
values in validating studies were poorest, we found about as many
(15) as we would have expected to find by chance (13). The t tests
used for assignment of primary nominal significance also correct
for assay variability. There is thus no indication that assay noise
provides the sole basis for the addiction-associated allelic variants
identified herein.
Overlap between Genes Identified Here and Those
Identified by Other Previously Reported GWA Datasets
The genes identified using approaches (1) or (2) each overlap
with genes identified in several other GWA datasets for substance
dependence, based on Monte Carlo simulations ([36] and
Materials and Methods). There are significant overlaps with data
from: a) 600k GWA studies of a subset of these polysubstance
abusers (p,0.001) [16], b) 500–600k GWA data from studies of
methamphetamine dependent Japanese samples [17] (p=0.04), c)
100k GWA data from studies of alcohol dependence in European-
Americans [15] (p=0.0003) and d) 38k data from comparisons
between more frequently nicotine dependent vs less frequently
nicotine dependent groups of smokers [37,38] (p=0.02). We also
identify substantial overlap with individually genotyped data from
dbGAP samples of cocaine dependent vs control individuals
(Table 2). This overlap is even more impressive when we compare
the genomic regions identified by clustered, nominally significant
results from samples of the same racial/ethnic group (Drgon et al,
in preparation).
Preferential Brain Expression of Genes Identified Here
We evaluated evidence for preferential brain and brain regional
expression patterns of the 104 genes identified in Table 2. Brain
libraries contained at least two expressed sequence tags (ESTs) that
corresponded to 79% (82/104) of the genes in Table 2. These
ESTs came from amygdala (255), adult brain (736), developing
brain (1243), caudate (striatum) (63), cerebellum (375), cerebral
cortex (52), hippocampus (554), hypothalamus (274), medulla
oblongata (31), substantia nigra (43), subthalamic nucleus (38),
thalamus (187), corpus callosum or other white matter (72) and
peripheral nerve (97). Levels of expression for this set of genes
(compared to all genes) displayed nominal significance in
thalamus, hippocampus, amygdala, cerebellum, substantia nigra,
hypothalamus and whole brain (p=0.002, 0.003, 0.004, 0.005,
0.02, 0.03 and 0.02, respectively). After Bonferroni corrections,
Table 1. Results of ‘‘converge first then cluster’’ (approach 1)
and ‘‘cluster first then converge (approach 2) analytic
strategies applied to substance dependence vulnerability
datasets described herein.
#SNPs Clustered SNPs
Number of
genes
Overlap with
104 genes
clust dist AfAm EuAm converg
CONVERGE FIRST, THEN CLUSTER (1)
3 25,000 937 104 104
3 10,000 299 37 37
4 25,000 328 31 31
4 10,000 86 10 10
CLUSTER FIRST, THEN CONVERGE (2)
3 25,000 55,507 47,614 18,552 1,546 104
3 10,000 29,009 25,523 5,353 802 79
4 25,000 44,881 37,927 12,562 1,015 92
4 10,000 17,849 15,779 2,142 341 52
Columns list the numbers of SNPs that display abuser vs control differences
with nominal p,0.05 (nominally positive) and lie in clusters, the maximal
distance between nominally positive SNPs that is considered to indicate
clustering, the numbers of clustered, nominally positive SNPs in African
American samples, the numbers of clustered, nominally positive SNPs in
European American samples, the numbers of ‘‘convergent’’ SNPs that display
nominally positive results in both samples, the fraction of ‘‘convergent’’ SNPs
that are likely to be true positives, on average, based on comparison with
randomly chosen SNPs that are selected for similar convergence analyses (data
not shown), the numbers of genes identified by the clusters of nominally
positive SNPs and the overlap between the genes in each set and the 104 genes
identified by the preplanned criteria used for primary analysis, using approach 1
with 3 SNP and 25kb intervals (boldfaced). The primary comparison set from
approach (2) is also listed in boldface, based on the similar fraction of true
positives anticipated using these criteria. We summarize these data in Fig. 2.
doi:10.1371/journal.pone.0008832.t001
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1: converge then cluster 2: cluster then converge dbGAP support
class/gene chr kbp gene description #SNPs p #SNPs AA/EA p # SNPs AA/EA
cell adhesion related
CDCP1 3 45098 CUB dom cont prot 1 3 0.021
FHIT* 3 59710 fragile histid triad 5 0.022 29/62 0.003 38/24
ODZ2 5 166644 odd Oz/ten-m hom 2 3 0.091 21/23 0.011 4/0
CSMD1* 8 2782 CUB Sushi mult dom 1 10 0.004 117/137 0.001 84/55
CSMD3 8 113304 CUB Sushi mult dom 3 4 0.033 4/5
CD274 9 5440 CD274 molecule 5 0.002 7/6 0.013
PCDH15 10 55250 protocadherin 15 3 0.094
CTNNA3* 10 67349 a 3 catenin 3 0.158 29/6 0.059 0/20
NRXN3 14 77939 neurexin 3 3 0.134 18/5 0.110 4/0
SEMA6D 15 45797 semaphorin 6D 7 0.001 14/7 0.005
THSD4 15 69220 thrombospondin I dom 4 3 0.067
CDH13* 16 81218 cadherin 13 3 0.104 76/65 0.001 0/5
DSCAM* 21 40306 Down synd cell adh mol 4 0.026 23/36 0.003 8/0
DNA/RNA handling
CHD1L 1 145180 chrdom h’case DNA bind1L 3 0.018 5/0
DDX1 2 15649 DEAD box polypept 1 3 0.019
PRPF4 9 115077 pre-mRNA proc fact 4 hom 3 0.012
PIWIL1 12 129388 piwi-like 1 3 0.019
POLR1D 13 27094 RNA pol I polypep D 3 0.019
SAMD4A 14 54104 ster a motif dom 4A 3 0.035
RAD51L1 14 67356 RAD51-like 1 3 0.073 4/10 0.112 0/8
enzyme
MKNK1 1 46795 MAP kin interact S/T kin 1 3 0.019
AGBL4 1 48822 ATP/GTP binding protL 4 6 0.008 10/8 0.040 7/0
NME7 1 167368 nucleoside-diP kin 14 0.001 22/25 0.001 0/8
QSOX1 1 178390 quiescin Q6 SH ox’ase 1 3 0.019 7/0
PRKCE 2 45732 protein kinase C epsilon 3 0.059 13/22 0.002 12/0
LASS6 2 169021 ceramide synthase 6 3 0.042
TMPRSS7 3 113236 serine TM protease 7 3 0.018
EHHADH 3 186391 3-OHAc coA dehydrog’ase 3 0.022 4/4
GBA3 4 22303 acidic ß glucosidase 3 6 0.003 5/5 0.042
PDE1C* 7 31795 calmod-dep P-diest’ase 1C 3 0.039
MSRA 8 9949 methionine SO red’ase A 3 0.047
ADARB2 10 1218 RNA-spec A deam’ase B2 3 0.061 5/9
SLK 10 105717 STE20-like kinase 3 0.019
PRKCH 14 60858 protein kinase C eta 5 0.008
XYLT1 16 17108 xylosyltransferase I 3 0.048 4/11 0.043 0/4
ligand
CXCL14 5 134934 chemokine ligand 14 4 0.005 5/5 0.020
protein handling/modification
TSSC1 2 3171 tumor sup subtrans cand 1 4 0.009 6/6 0.034
FKBP15 9 114967 FK506 binding protein 15 4 0.006
HSPA12A 10 118419 HSP 12A 3 0.020 10/15 0.004
BRWD2 10 122600 bromodom WD dom 2 3 0.022
DOCK1 10 128658 ded cytokinesis 1 3 0.051 0/7
PACS1 11 65594 Pfurin sort prot 1 4 0.010 7/9 0.019
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class/gene chr kbp gene description #SNPs p #SNPs AA/EA p # SNPs AA/EA
CCDC91 12 28301 coiled-coil dom 91 10 0.001 5/17 0.012
XPO6 16 28016 exportin 6 4 0.006 12/5 0.011
PMAIP1 18 55718 PMA-induced prot 1 3 0.011 4/4 0.041
receptor
OPRD1 1 29011 d opioid rec 1 6 0.001 10/6 0.011
PLA2R1 2 160506 Pipase A2 rec 1 4 0.006
GRM7* 3 6877 metabo glut rec 7 3 0.083 4/5 0.226 9/34
GRIK2 6 101953 ino glut rec kainate 2 3 0.071 5/4 0.191 10/0
OR51E1 11 4630 olfactory rec 51 E 1 3 0.011
LDLRAD3 11 35922 low dens lipoprot rec A 3 3 0.042 13/6 0.020 6/0
GRM5 11 87880 metabo glut rec 5 5 0.011 20/7 0.015 5/0
GRIA4 11 104986 ino glut rec AMPA 4 3 0.048
COLEC12 18 309 collectin sub-fam 12 3 0.031
INSR 19 7067 insulin rec 3 0.032
signaling
BCAR3 1 93799 br ca anti-est res 3 3 0.025
TTC21B 2 165905 tetratricopept rep dom 21B 4 0.020 8/4 0.118 10/12
TIAM2 6 155453 T-cell lymph inv met 2 3 0.032
FAM126A 7 22949 fam seq similar 126 A 3 0.022 6/4 0.032
ANO4 12 99712 anoctamin 4 3 0.041 0/5
APPL2 12 104091 pY inter PH dom leu zip 2 3 0.021 9/0
structure
INADL 1 61980 InaD-like 3 0.048 0/9
LIMCH1 4 41057 LIM calpon homol dom 1 3 0.045
DNAH8 6 38798 dynein h polypept 8 4 0.012 5/4 0.090 4/0
MYO6 6 76515 myosin VI 3 0.029 4/4 0.091
AKAP7 6 131508 A kinase anchor prot 7 4 0.008 4/7 0.040
SYNE1 6 152484 spectrin rep nuc env 1 3 0.058 26/5 0.007 6/7
CADPS2 7 121746 Ca-dep act prot secret 2 3 0.063
CHCHD3 7 132120 coil-coil-helix dom 3 3 0.039 7/4 0.064
MPP7 10 28382 palmitoyl memb prot 7 3 0.033
ABLIM1 10 116180 actin bind LIM protein 1 3 0.040
PARVA 11 12355 a parvin 4 0.010 4/12 0.018
CSRP3 11 19160 C G-rich prot 3 3 0.016
FARP1 13 97593 FERM RhoGEF pleckst 1 3 0.043
MYO5C 15 50271 myosin VC 3 0.023 4/9 0.027
FHOD3 18 32131 formin homol 2 cont 3 3 0.056 0/12
transcription regulation
PBX1 1 162795 pre-B-cell leukemia TF 1 5 0.005
AFF3 2 99530 AF4/FMR2 3 3 0.063
CSRNP3 2 166137 cys-ser-rich nuclear prot 3 3 0.029 3/3 0.081 6/0
ZNF804A 2 185171 zinc finger protein 804A 4 0.011 4/4 0.141
ZNF385D 3 21437 zinc finger protein 385D 3 0.042 12/4 0.033 0/5
ZNF366 5 71774 zinc finger protein 366 8 0.001 7/11 0.008
ETV6 12 11694 ets variant gene 6 3 0.038 4/25 0.004
KLF12 13 73158 Kruppel-like factor 12 4 0.015 4/7 0.094
ZNF606 19 63180 zinc finger protein 606 3 0.017
LDOC1L 22 43267 L zip down-reg ca 1-L 3 0.012 5/4 0.028
transport
Table 2. Cont.
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respectively) retained significance. Assessments of the ‘‘more
reliable’’ subset of ESTs revealed significant over expression in
hippocampus and whole brain (corrected p ca 0.01 for each).
Discussion
‘‘Replication’’ of Genome Wide Association Results
Genome-wide association data of increasing richness is available
for a number of complex disorders. Several of these GWA datasets
contain relatively robust results at ‘‘oligogenic’’ loci that can also
be identified by linkage-based approaches [39–42]. Even moder-
ately secure GWA identification of ‘‘polygenic’’ influences on
disease, however, is likely to require replicated data from multiple
independent samples.
There have been no unanimous criteria for declaring such
replication in circumstances in which no SNP provides ‘‘genome
wide significance’’ with the same phase of association in
‘‘template’’ GWA analyses of data from multiple independent
samples. Replication of nominally significant associations for the
same SNP (approach (1), here) is among the criteria most used to
date [43,44]. This ‘‘nontemplate’’ GWA analytic approach is likely
to perform best when large association signals are found in each
independent sample, when the same SNP sets are studied in each,
when the disease exhibits little locus heterogeneity and when there
are good matches between the fine patterns of linkage disequilib-
rium of the samples being studied and the reference samples
(commonly, Hap Map) used to infer the underlying patterns of
linkage disequilibrium. Few ‘‘replication’’ samples manifest all of
these features. Although the current European- and African-
American samples were recruited in parallel and evaluated with
the same SNPs, the racial/ethnic differences between the
participants suggest that the samples are likely to manifest
differences in fine patterns of linkage disequilibrium and in phase
of association at many loci. Apparent replication ‘‘failures’’ using
approach (1) could thus relate to sample-to-sample differences in
fine patterns of linkage disequilibrium and/or different amounts of
information provided by markers with population-specific differ-
ences in allele frequencies. Allelic heterogeneities could also make
contributions. Conceivably, genes for which the Monte Carlo p
values determined by approach (2) are much stronger than the
estimates based on approach (1) might provide interesting
candidates for such allelic heterogeneity. Positive findings in the
‘‘cluster than converge’’ approach that are supported by evidence
from other studies might be especially attractive candidates.
NRXN3 and GABBR2 were identified using this approach and
also in linkage studies of opiate dependence [45] and association
studies of nicotine dependence [6,46], for example.
1: converge then cluster 2: cluster then converge dbGAP support
class/gene chr kbp gene description #SNPs p #SNPs AA/EA p # SNPs AA/EA
ATP1B1 1 167342 Na/K transpor ATPase ß 1 4 0.004 4/4 0.053 0/3
SLC45A2 5 33980 solute carrier 45 2 4 0.005 11/0
CFTR 7 116907 ATP-binding cassette C 7 3 0.033 5/0
XKR4 8 56177 Kell blood gp comp 4 3 0.051 8/8 0.043
SLC2A13 12 38435 solute ligand carrier 2 13 6 0.004 17/4 0.019 0/8
ABCC4* 13 94470 ATP-binding cassette C 4 4 0.012 13/4 0.023 23/30
SLC10A2 13 102494 solute ligand carrier10 2 3 0.014 12/7 0.005 0/8
unknown
KIAA1276 4 17242 KIAA1276 protein 3 0.029
FLJ44606 5 126411 FLJ44606 3 0.016 5/4 0.034
FAM184A 6 119322 fam seq sim 184 A 3 0.028
BRP44L 6 166698 brain protein 44-L 3 0.015
FRMD4A 10 13725 FERM dom 4A 3 0.071 4/23 0.021 5/13
C10orf11 10 77212 Ch 10 ORF 11 3 0.077
C10orf82 10 118413 Ch 10 ORF 82 3 0.013 5/6 0.017
C19orf18 19 63161 Ch 19 ORF 18 3 0.013
MACROD2 20 13924 MACRO dom 2 3 0.175 57/22 0.004 6/8
C20orf70 20 31219 Ch 20 ORF 70 3 0.014
RHBDD3 22 27985 rhomboid dom 3 3 0.014
These ‘‘converge then cluster’’ genes thus each contain three or more SNPs that display nominally significant allele frequency differences between both European-
American (EA) and African-American (AA) polysubstance abuser vs control comparisons that cluster within ,25kb of each other and lie within the gene’s exons or
within +/210 kb 39 or 59 flanking sequences. Genes are grouped by the class of the function to which they contribute. The numbers of reproducibly positive SNPs that
lay in clusters within the gene’s exons and in 10 kb genomic flanking regions are noted. Chromosome number and initial chromosomal position for the cluster (bp, NCBI
Mapviewer Build 36.1) are listed. ‘‘Approach 2/Cluster then converge’’ genes that were identified by clusters of at least 4 nominally positive SNPs that lay within 10kb of
each other and lay within the gene for each sample are listed in the column labeled ‘‘2: cluster then converge’’. Asterisk identifies genes also identified in [16]. P
values are based on 10,000 Monte Carlo simulation trials in which the number of times randomly-selected segments of the genome that lie within genes are assessed
for the same features displayed by the actual gene identified. Relevant rs numbers for SNPs are listed in Table S2. dbGAP support lists the numbers of SNPs in the same
genes that display nominally-significant differences between cocaine-dependent and nondependent control AA and EA samples from 1M SNP Illumina individual
genotyping of samples from COGA, FSCD and COGEND samples as described in dbGAP (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gap).
doi:10.1371/journal.pone.0008832.t002
Table 2. Cont.
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Results from approaches (1) and (2) share a number of potential
strengths. These datasets provide significant concordance with
each other, with previous GWA datasets for substance depen-
dence, and with dbGAP data that has been available only after the
results of the current study were analyzed. The arrays used here
provide power to identify many of the genes, especially genes of
smaller size, which could not have been identified in previous
GWA studies that used analysis (1) and lower density arrays [25].
Monte Carlo methods allow us to test the probabilities of chance
clustering of nominally positive SNPs and the chance of
convergence between clusters identified in one sample with
clusters identified in other samples. Our Monte Carlo approaches
deploy an empirical method that uses the existing dataset as a
source for randomly selected SNPs for each Monte Carlo trial.
The results of these simulations, supported by data derived from
permutation, principal components and other analyses, provide
strong overall confidence that these results are not due to chance.
By contrast, these approaches provide absolutely unequivocal
identification for few individual SNPs. This lack of unequivocal
identification of individual SNPs is consistent with the current
polygenic working models for the genetic architecture of
vulnerability to substance abuse [25,47].
Differences between ‘‘Non-Template’’ and ‘‘Template’’
GWA Approaches
Validation studies provide evidence for excellent correlations
between individually genotyped and pooled allele frequency
assessments. However, the current ‘‘nontemplate’’ approaches and
data do provide a number of differences from the ‘‘template’’
genome wide association approaches used in recent reports from
larger projects that employ individual genotyping in studies of legal
phenotypes, for example the GWA studies of complex phenotypes
currently listed in dbGAP (http://www.ncbi.nlm.nih.gov/sites/
entrez?Db=gap). 1a) The samples for these studies are typically
compiled from recruitments at many sites. The studies typically
combine subjects recruited based on multiple sets of criteria for
selection. There is no indication of the fraction of individuals
approached who consented. Cases are compared to controls who
were almost always recruited and collected at different times and are
either uncharacterized or evaluated using methods different from
those applied to cases. 1b) By comparison, all of the dependent and
control individuals studied in the present sample were collected at
the same site, recruited in ways that result in virtually all candidates
consenting to participation, and assessed using the same instruments.
Controls are thus characterized in such a manner that they each
provide a contrast with the dependent cases. 2a) Genotyping data in
dbGAP typically uses data from single microarrays that are
hybridized with fluorescently-labeled DNAs prepared from DNAs
from single individuals, hybridization intensities assessed, and
genotype calls made based on Bayesian and other algorithms using
data from the ratios of hybridization intensities to probes that are
complementary to alternative allelic forms of each SNP. Quality
control efforts for samples and SNPs use predetermined algorithms
for hybridization signal differences and analyses of Hardy-Weinberg
equilibria. Few studies provide test-retest data to evaluate the
fraction of genotypes that are replicable, however. 2b) The current
approach uses data from three microarrays that are hybridized with
three distinct preparations of fluorescently labeled DNA that are
carefully prepared from pools of DNA from 20 individuals. Quality
control evaluations come chiefly from assessment of the array-to-
array variation in hybridization intensities noted for replicate
experiments, as well as assessments of pool-to-pool variation, as
noted here. These assessments thus do not measure the features that
are assessed by Affymetrix or Illumina software packages, but rely
on estimates of variability in relation to the signals obtained. The
0.98+ correlation between observed ande x p e c t e da l l e l ef r e q u e n c i e s
p r o v i d e sam o d e s td i f f e r e n c ef r o mas e to fp e r f e c t l ya c c u r a t e
individual genotypes. 3a) The sample sizes in studies currently listed
in dbGAP are larger, with an average size of 2,155 cases and
controls 3b) The sample size here of 1,620 is divided into two
separate case vs control comparisons, providing, as we note,
moderate power to detect replicable modest-sized effects and lower
power to detect very small effects. True effects that provide nominal
statistical significance in clustered SNPs in only one sample represent
false-negative findings in our first analysis. 4a) Many of the results of
individually-genotyped studies represented in dbGAP are analyzed
based on the assumption that the detailed haplotype structures
identified in data from CEPH and Yoruban individuals will provide
accurate representations of the haplotypes identified in European-
American and African-American samples identified far from Utah.
4b) The approach that we use here is based on distances between
SNP genomic markers, rather than assumptions about the extent to
which the exact haplotype structure of these reference populations
will be maintained in the samples that we have studied. 5a) Dense
individual genotypes provide the opportunity for unequivocal
matching with DNA databases; 5b) Pooled genotypes provide a
much stronger barrier for matching with DNA databases, which is
an enhanced consideration in studies of illegal behaviors. 6a)
‘‘Template’’ analyses focus on strength of association for individual
SNPs; 6b) The current analyses assume that most bona fide
associations that are based on phenotypic differences will be present
at multiple nearby SNPs. In any single sample, many of the clusters
of positive findings at nearby SNPs could be due to stochastic
differences in haplotype frequencies between cases and controls that
are not related to phenotype. As the same chromosomal regions are
identified by more and more independent samples, however, the
likelihood that such identification is due to stochastic differences in
haplotype frequencies that are unrelated to phenotype declines
sharply. Assessment in multiple, independent samples, as we
perform here, provides the best control for stochastic differences
in haplotype frequencies that might be expected, by chance,
between any single case and control samples. 7a) ‘‘Template’’ GWA
analyses that focus on single SNPs may provide modest biases
toward identification of large genes that contain many SNPs; 7b)
The current analyses require nominally significant associations for
multiple SNPs that lie within narrow chromosomal regions. A
number of the smallest genes cannot be identified by this approach
[25], in ways that might lead to an even more prominent bias
toward identification of larger genes in this way; 8a) ‘‘Template’’
GWA approaches focus on metaanalyses as means to evaluate
convergence of data from single SNPs across many independent
samples; 8b) As more such data becomes available, metaanalyses
can be applied to the current results. However, in the relative
absence of other GWA datasets (but see below), metaanalyses are of
more limited utility.
Genes Also Identified in Other Studies of Addiction
Despite the differences in approaches, primary substance of
abuse and/or genetic background, however, there is significant
evidence that, compared to chance, the current results identify
more of the same genes and chromosomal regions that are also
identified by a number of independent datasets that compare
substance dependence phenotypes to controls. These include the
fits between the current nontemplate analyses of data from pooled
African- and European-American samples and previously-report-
GWA in Addiction
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samples as well as individual genotyping results that compare
dependent vs nondependent smokers. Analyses of cocaine
dependence vs control data that has become available on dbGAP
after our analyses were completed provide support for 162 of the
clusters of nominally-positive result from the European-American
samples reported herein by clusters of at least 4 SNPs that display
p,0.05 nominal significance in this dbGAP data (Monte Carlo
p,0.0001) (Drgon et al, in preparation). Data for African-
American samples provides support for 147 of the clustered,
nominally significant observations from our current report (Monte
Carlo p,0.0001) (Drgon et al, in preparation).
Our identification of some SNP markers whose allelic frequencies
distinguish controls from addicts of different ethnicities supports
‘‘common disease/common allele’’ genetic architecture for signif-
icant portions of addiction vulnerability [48] based on relatively old
allelic variants. The good fits between results from ethnically-
matched samples from the current data and dbGAP samples also
support the idea that many addiction vulnerability variants are
likely to display substantial differences from one human population
to another (Drgon et al, in preparation). In our current data, the
same phase is not detected for many of the SNP associations noted
in samples of different racial/ethnic backgrounds. Although we
believe that this is a likely consequence of the differences in detailed
linkage disequilibrium between the SNP markers and the actual
pathogenic allelic variants at many of these chromosomal loci, some
of these phase differences are also likely to reflect results that co-
occur in the two independent samples by chance.
The convergent data derived from studies of individuals with
addictions to substances in several different pharmacological
classes support the idea that many of these allelic variants enhance
vulnerability to many addictions. These results do not exclude
additional contributions to addiction vulnerability from genomic
variants that influence vulnerability to specific substances or
variants that are found only in specific populations, however.
Classes of Genes Identified Here
We focus on identification of genes. Although associations in
chromosomal regions that do not contain annotated genes also
provide interesting results, the genes that we identify in the present
work provide a number of interesting views of addiction. 1) More are
r e p r e s e n t e da m o n gc D N A sc l o n e df rom brain libraries than is the
case for all human genes. While all do not display at least two
cDNAs in at least one brain library represented in dbEST, it seems
likely that many of the remaining genes are expressed at low levels
and/or in small brain regions that are not adequately represented in
many of these libraries. 2) The results from dbEST studies of the
expression of these genes focus attention on expression in
hippocampus, which manifests interesting roles in mnemonic
processes in ways that may provide clues to the pathophysiology
of human addiction. 3) These genes do not overlap, to extents
greater than expected by chance, with genes listed in the
Knowledgebase for Addiction Related Genes (KARG), a recent
compilation of literature and database information concerning
addiction related genes [49]. 4) Gene ontology searches (BioBase)
reveal ‘‘Biological Process’’ terms that displayed the strongest
trends toward overrepresentation (compared to Bonferroni-
corrected p=7.8610
25) among human gene classes: glutamate
signaling pathway (p=0.00019); auditory receptor cell differen-
tiation (p=0.0047); endocytosis (p=0.0065); sex determination
(p=0.0081); inner ear receptor cell differentiation (p=0.0081);
endothelial cell proliferation (p=0.0088); synaptic transmission
(p=0.01); mechanoreceptor differentiation (p=0.01); adult locomo-
tor behavior (p=0.01) and regulation of synaptic plasticity (p=0.01).
Mouse data for glutamate signaling pathway (p=8.2610
26)
provides the strongest p values that do exceed the Bonferroni
correction (data not shown).
Identification of cell adhesion molecule genes, which are
represented in several of the above mentioned gene classes
(Table 2) continues to focus our attention on roles in addiction for
mechanisms for establishing and regulating neuronal connections
[50–52]. These data accord well with prior results that link
substance dependence to 59 NrCAM variants that alter levels of
expression and to 39 NRXN3 variants that alter relative levels of
splicing isoforms [45,53]. It is important to note that these cell
adhesion genes are generally large, providing more opportunities
for allelic variants that could alter their functions in a number of
fashions. It is interesting to note that recent analyses of all reported
genome wide association datasets also identified overrepresenta-
tion of cell adhesion molecule genes [54].
We also identify genes that are likely to be readily targeted and
modulated by drugs, and thus provide potential pharmacothera-
peutic targets for addictions. G protein coupled receptors that
include the d opioid receptor and metabotropic glutamate receptor
5 display rich pharmacologies and substantial ties to addiction
through abundant evidence from pharmacologic, knockout mouse
and other approaches. Glutamatergic systems are also implicated
by identification of ‘‘druggable’’ metabotropic 7, GRIK2 kainate
and GRIA4 AMPA glutamate receptors, as well as several cell
adhesion molecules that are associated with classical synapses.
Known small molecules and/or drugs act at many of the other
receptors, enzymes and transporters listed in Table 2.
Genes Also Identified in Studies of Heritable,
Co-Occurring Phenotypes
A number of the genes identified in this work are also identified
in genome wide association and/or candidate gene datasets for
heritable disorders or phenotypes that co-occur with addictions
[25]. Differences in memory and cognitive systems have long been
identified in addicted individuals; we have identified significant
overlaps between the addiction associated genes listed below and
the results of GWA studies for individual differences in cognitive
abilities. NRXN3 and a number of other genes listed in Table 2
also display associations with the memory-associated neurodegen-
erative disorder, Alzheimer’s disease (Hishimoto et al, submitted).
Frontal lobe volumes are smaller in several studies of substance
dependent individuals or their offspring; there is significant overlap
between GWA results for frontal lobe volumes and addiction [25].
Overall GWA results for bipolar disorder, in which a majority of
individuals may abuse or be dependent on addictive substances,
overlap with addiction GWA data [25]. There is also a significant
overall overlap between addiction vulnerability GWA data and the
genes identified in studies of success in smoking cessation [25].
Conclusions
The findings presented here promise to add to the ongoing
consideration of methods for comparing GWA datasets as they
enhance understanding of genetic underpinnings of human
addiction. For addictions, as for many complex disorders, such
data provides an increasingly rich basis for improved understand-
ing and for personalized prevention and treatment strategies.
Materials and Methods
NIDA Research Volunteers
Research volunteers who came to the NIDA research facility in
Baltimore, Maryland between 1990 and 2007 in response to
advertisements and referrals from other research volunteers
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drug use histories via the Drug Use Survey and DSMIII-R or IV
diagnoses and were reimbursed for their time at different rates
during this period (currently about $120 total) as previously
described [13,55,56]. DNA in 81 pools sampled: a) 400 unrelated
European-American ‘‘abusers’’ (mean age and standard devia-
tion=34 (+/22), 0.79 male) with heavy lifetime use of illegal
substances and, for virtually all, DSMIII-R/IV dependence on at
least one illegal abused substance b) 280 ‘‘control’’ European-
Americans (mean age 32 (+/23), 0.6 male) who reported no
significant lifetime use of any addictive substance, c) 700 African-
American abusers (mean age 34 (+/23), 0.75 male) and d) 240
African-American controls (mean age 35 (+/25), 0.43 male)
[13,14,16]. The modest differences between mean ages of
dependent and control individuals would be expected to yield
virtually no differences in cumulative lifetime probabilities of
developing dependence on one or more illegal substances, based
on data from the National Survey of Drug Use in Households
(http://oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.cfm#TOC).
DNAs were assessed in pools since this: 1) provided us with the
maximal ability to protect the genetic confidentiality of subjects
who volunteered for study of genetics of illegal behaviors, 2)
allowed us to utilize DNAs from individuals who consented to
participation in this study during time periods when consents did
not explicitly describe studies using high densities of DNA
markers, 3) allowed us to utilize DNAs from individuals whose
consents explicitly committed us to use DNA pooling methods
wherever possible to maximize protection of their genetic
confidentiality, 4) allowed us to use methods that we have
developed and validated in this and in previous work and 5)
reduced costs. Most of these subjects would thus not have been
available for studies that assessed substantial numbers of
polymorphisms using individual genotyping.
DNA was prepared from blood [13,55,56]. Genotyping and
primary assessments of genotyping were performed by investiga-
tors blinded to clinical diagnoses. DNAs from groups of 20
individuals of the same ethnicity and phenotype were carefully
quantitated and combined. This number of individuals/pool was
selected since we have extensively validated use of pools of this size
[13–17,37,38] with respect to statistical power as well as the
advantages and disadvantages of pooling noted above. Hybrid-
ization probes were prepared as described (Affymetrix assay 6.0,
[15]). For each pool 150 ng of pooled DNA was processed, labeled
and hybridized to Affymetrix 6.0 arrays according to the
instructions of the manufacturer (Affymetrix, Santa Clara CA)
and [13–15]. Quality controls for assays were performed as
recommended (Affymetrix, Santa Clara CA) and (Fig. S2).
Features of this portion of methods are depicted in Fig. S1.
Identification of Nominally-Positive SNPs
For NIDA individuals allele frequencies for each SNP in each
DNA pool were assessed based on hybridization to the 3–4
‘‘perfect match’’ cells on each of three arrays, as described [14,15].
We validated this approach (Fig. 1) [14,15]. The intensities of the
highest and lowest 5% of features on each array were monitored
and the variances in signal between replicate hybridizations of
DNA from each pool and between hybridization signals from
pools of the same phenotype and ethnicity were assessed. For the
detection of nominally positive SNPs we averaged the ‘‘perfect
match’’ data for each SNP on each array, derived the arctangent
of the ratio between hybridization intensities for A and B alleles,
averaged the arctan A/B values for the three replicate arrays,
divided the mean arctan A/B ratios for abusers by the mean
arctan A/B ratios for controls to form an abuser/control ratio for
each SNP, and generated a ‘‘t’’ statistic for the differences between
arctan A/B in abusers and controls with corresponding p values
(see Fig. S1 for this portion of the ‘‘cluster then converge’’ analysis
and Fig S2 for initial quality control).
We deleted data from SNPs on sex chromosomes. This allowed
us to combine data from male and female subjects and increase
overall power. We also deleted data for SNPs whose chromosomal
positions could not be adequately determined.
Identification of Genes That Contained Convergent Data
from Two Samples: 1) ‘‘Converge Then Cluster’’
For these analyses, we identified ‘‘reproducibly-positive’’ SNPs
that cluster in small genomic regions within genes (Table 1). These
SNPs a) display t values with p,0.05 significance in both African-
and European-American abuser vs control comparisons (we define
this evidence for significant association in each of two independent
samples as ‘‘reproducible’’), b) cluster, so that at least three
reproducibly-positive SNPs lie within 25kb of other reproducibly-
positive SNPs, c) identify genes (Table 2, legend). The 104 genes in
Table 2 are supported by reproducible clustered positive
association data from the same SNPs in each of two samples.
We identify subsets of these genes when we impose more stringent
criteria for: a) #10,000 basepair distances between reproducibly-
positive SNPs, and b) at least 4 nominally-positive SNPs per cluster
(Table 1).
Identification of Genes That Contained Convergent Data
from Two Samples: 2) ‘‘Cluster Than Converge’’
To provide complementary analyses, we began by identifying
clusters of positive SNPs that fall within genes in each sample. We
identify the genes that are tagged by at least one cluster of
nominally positive SNPs from each of the two samples (Table 1).
We focus on a set of criteria for approach (2) that produce about
the same ratio of ‘‘true’’ genes to total genes (‘‘true’’+‘‘chance’’)
(0.43 vs 0.47) as those likely to be observed using the criteria on
which we focused in approach (1). The SNPs that we identify in
this secondary analysis thus a) display t values with p,0.05
significance in one abuser vs control comparison, b) cluster, so that
at least four of these positive SNPs lie within 10kb of each other in
this abuser vs control comparison, c) identify the same genes as
clustered positive SNPs from the other sample (Table 2, legend, and
Table S1). Three hundred forty one genes are identified in this
way (Table S1). Fifty-two of the 104 genes listed in Table 2 based
on approach (1) are also identified after application of the criteria
noted above and approach (2). See Fig. S1 (points 4–6) for details
of the last steps of ‘‘cluster then converge’’ analyses:
The sets of results from approaches (1) and (2) were compared to
those expected by chance using 100,000 Monte Carlo II
simulation trials (below) ([36] and below, and Johnson et al, in
preparation). For each of 100,000 simulation trials, a random set
of SNPs was chosen by sampling randomly from a list that
contained all SNPs studied. The randomly chosen SNPs were
considered ‘‘pseudopositive’’ SNPs for that trial. The number of
trials for which the results from ‘‘pseudopositive’’ SNPs subjected
to our analytical procedure matched or exceeded the results
actually observed from the SNPs identified in the current study
was tabulated. Empirical p values were calculated by dividing the
number of trials for which the observed results were matched or
exceeded by the total number of Monte Carlo simulation trials.
Similar Monte Carlo III approaches ([36] and below) sampled
from a dataset of all gene sequences. These approaches allowed us
to generate nominal p values for the observations made for each
gene listed in Table 2.
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extent to which clustering of nominally positive SNPs (from each
of 2 samples in ‘‘converge then cluster’’ approach and from each
sample in ‘‘cluster then converge’’ approach) differed from chance.
Monte Carlo II assessments [36] provided p values for the degree
to which clusters identified in one of the samples from the ‘‘cluster
then converge’’ approaches were found in the same genes as those
identified by clusters from the other sample. Monte Carlo III
assessments [36] provided p values for the likelihood of finding of
sets of nominally-positive SNPs in segments of each of the genes
identified here (Johnson et al, in preparation).
Secondary analysis used permutation approaches. We random-
ized assignment of the phenotypes to data derived from the
current SNPs and analyzed the data in each of the 10,000
permutation trials.
To assess the power of our current approach we used current
sample sizes and standard deviations, power calculator PS v2.1.31
[57,58] and a=0.05. Results from ‘‘Gene detective’’ [25]
provided a secondary power assessment.
To provide controls for the possibility that observed abuser-
control differences were due to a) occult ethnic/racial allele
frequency differences or b) noisy assays, we assessed the overlap
between our results and SNPs that displayed the largest a)
allele frequency differences between African-American vs
European-American control individuals and b) the largest
assay ‘‘noise’’.
To seek patterns of human brain expression for the genes
identified herein, we identified 846 human cDNA libraries
constructed from brains with modest or no pathology in dbEST.
We identified 1) all entries and 2) ‘‘more reliable’’ entries with
correct genomic orientation and either evidence for polyA tail or
spliced structure (CYL and GRU, in preparation). For each brain
region, we assessed the p-value for over-representation of
expression of the addiction-associated genes using hypergeometric
distribution tests and false discovery rate (FDR) corrections,
considering Q-values,0.05 as statistically significant.
dbGAP Samples from the Family Study of Cocaine
Dependence, COGA and COGEND Studies
Unrelated subjects who met DSM criteria for cocaine
dependence and control subjects with no evidence for dependence
on any addictive substance were assembled from three studies.
Family study of cocaine dependence subjects were recruited from
treatment centers close to St. Louis. Mo; 55% of contacted
subjects participated. Community-based comparison subjects were
recruited through driver’s license records from the Missouri
Family Registry and were matched to cocaine dependent subjects
based on date of birth, ethnicity, gender, and zip code. Eighty
percent of screened and eligible comparison subjects participated.
Other participants came from individuals who participated in the
collaborative study on the genetics of alcoholism and the
collaborative study on the genetics of nicotine dependence.
Dependent individuals displayed DSM dependence on cocaine
as reflected in the dbGAP variable phv00066444.v1.p1. Controls
displayed no DSM dependence on cocaine, nicotine, alcohol,
marijuana, opioids or other drugs. We identified 481 dependent
and 1053 control unrelated European-American and 516
dependent and 409 control unrelated African-American subjects
for this analysis. Genotyping for these samples was performed
using Illumina 1M SNP arrays at the Center for Inherited Disease
Research (CIDR), with quality controls and principal components
analysis (PCA) controls for racial/ethnic background available at
the CIDR website (www.cidr.jhmi.edu). Genotypes from depen-
dent and control individuals were selected from dbGAP files. p
values for each SNP were based on x
2 tests. The resulting p values
were then analyzed and compared to the results from the NIDA
individuals by the ‘‘cluster then converge’’ method described
above.
Gene Ontology analysis was performed in BioBase Systems
Biology Environment (http://www.biobase.de) installed on
http://helixweb.nih.gov/biobase.
Supporting Information
Figure S1 Simplified schematics for methods used in the current
analyses. A: Methodological schematic. First two lines denote
separation of African-American and European-American samples
into ‘‘case’’, ‘‘control’’ and ‘‘other’’ phenotypes. Third line denotes
pooling DNAs from groups of 20 individuals of the same racial/
ethnic and phenotype group. Lines 4–6 denote analyzing DNA
from each of the pools using three independent Affymetrix 6.0
array assays. B: Analytic schematic. Points 1–3 and ‘‘Manhattan
plots’’ indicate analyses that identify SNPs with nominally-
significant case vs control differences. Point 4a: Converge then
cluster analysis. Point 4b: Cluster then converge analysis. Point 5
emphasizes gene-centered analysis used herein.
Found at: doi:10.1371/journal.pone.0008832.s001 (0.07 MB
PDF)
Figure S2 QQ plots for distribution of t values from African-
American data (left) and European American data (right).
Observed data from these experiments provides deviations from
expected data generated from 10,000 t tests which were each run
from a set of random values of the same size as those obtained
from the true datasets. Deviations noted at the right side of these
plots are likely to represent both a) true case vs control differences
and b) nonnormal differences in the distribution of t values from
the bona fide data. In the current ‘‘nontemplate’’ analyses, we use
t values to identify the 5% of SNPs with the highest t values and
subsequent testing with empirical statistics to assign overall levels
of significance. Thus, any nonnormal component of this
distribution is of less concern than it would be for ‘‘template’’
GWA analyses in which t values might be used as the primary
determinant of (e.g., genome wide) significance.
Found at: doi:10.1371/journal.pone.0008832.s002 (0.03 MB
PDF)
Table S1 Genes identified by ‘‘cluster then converge’’ secondary
analyses (2), as described in the text. These genes are thus each
identified by clusters of four or more SNPs that display nominally
significant allele frequency differences between polysubstance
abuser vs control comparisons, cluster within ,10kb of each
other and lie within the gene’s exons or within +/210 kb 39 or 59
flanking sequences. Note that for this analysis, the same SNPs are
not required to display nominal significance in each of the two
samples. p values are based on 10,000 Monte Carlo simulation
trials in which the number of times randomly-selected segments of
the genome that lie within genes are assessed for the same features
displayed by the actual gene identified. Some, but not all, of these
genes are also identified by (1) converge then cluster analyses as
noted in Table 1 and by clustered nominally-significant SNPs from
dbGAP datasets, as noted in Table 2.
Found at: doi:10.1371/journal.pone.0008832.s003 (0.04 MB
PDF)
Table S2 List of RS numbers and chromosomal location
identified as ‘‘positive’’ that are the basis for identification of the
genes in Table 2 in the manuscript.
Found at: doi:10.1371/journal.pone.0008832.s004 (0.03 MB
PDF)
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